Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1002/adtp.202000210 http://scihub22266oqcxt.onion/10.1002/adtp.202000210 33786368!7995185!33786368     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Adv+Ther+(Weinh) 2021 ; 4 (4): 2000210 Nephropedia Template TP {{tp|p=33786368|t=2021. Sulfoglycodendrimer Therapeutics for HIV-1 and SARS-CoV-2 |pdf=|usr=}}{{33786368}} gab.com Text Sulfoglycodendrimer Therapeutics for HIV-1 and SARS-CoV-2 JO: Adv Ther (Weinh) http://www.kidney.de/pget.php?&tw=1&pmid=33786368 #FOAvip Hexavalent sulfoglycodendrimers (SGDs) are synthesized as mimics of host cell heparan sulfate proteoglycans (HSPGs) to inhibit the early stages in viral binding/entry of HIV-1 and SARS-CoV-2. Using an HIV neutralization assay, the most promising of the seven candidates are found to have sub-micromolar anti-HIV activities. Molecular dynamics simulations are separately implemented to investigate how/where the SGDs interacted with both pathogens. The simulations revealed that the SGDs: 1) develop multivalent binding with polybasic regions within and outside of the V3 loop on glycoprotein 120 (gp120) for HIV-1, and consecutively bind with multiple gp120 subunits, and 2) interact with basic amino acids in both the angiotensin-converting enzyme 2 (ACE2) and HSPG binding regions of the Receptor Binding Domain (RBD) from SARS-CoV-2. These results illustrate the considerable potential of SGDs as inhibitors in viral binding/entry of both HIV-1 and SARS-CoV-2 pathogens, leading the way for further development of this class of molecules as broad-spectrum antiviral agents. Twit Text FOAVip Sulfoglycodendrimer Therapeutics for HIV-1 and SARS-CoV-2 ????Adv Ther (Weinh) http://www.kidney.de/pget.php?&tw=1&pmid=33786368 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33786368 #FOAvip English Wikipedia <ref>{{Cite pmid|33786368}}</ref> Sulfoglycodendrimer Therapeutics for HIV-1 and SARS-CoV-2 #MMPMID33786368 Wells L; Vierra C; Hardman J; Han Y; Dimas D; Gwarada-Phillips LN; Blackeye R; Eggers DK; LaBranche CC; Kral P; McReynolds KD Adv Ther (Weinh) 2021[Apr]; 4 (4): 2000210 PMID33786368show ga Hexavalent sulfoglycodendrimers (SGDs) are synthesized as mimics of host cell heparan sulfate proteoglycans (HSPGs) to inhibit the early stages in viral binding/entry of HIV-1 and SARS-CoV-2. Using an HIV neutralization assay, the most promising of the seven candidates are found to have sub-micromolar anti-HIV activities. Molecular dynamics simulations are separately implemented to investigate how/where the SGDs interacted with both pathogens. The simulations revealed that the SGDs: 1) develop multivalent binding with polybasic regions within and outside of the V3 loop on glycoprotein 120 (gp120) for HIV-1, and consecutively bind with multiple gp120 subunits, and 2) interact with basic amino acids in both the angiotensin-converting enzyme 2 (ACE2) and HSPG binding regions of the Receptor Binding Domain (RBD) from SARS-CoV-2. These results illustrate the considerable potential of SGDs as inhibitors in viral binding/entry of both HIV-1 and SARS-CoV-2 pathogens, leading the way for further development of this class of molecules as broad-spectrum antiviral agents. äSulfoglycodendrimer Therapeutics for HIV-1 and SARS-CoV-2 (epmc).pdf DeepDyve Pubget Overpricing